| Executive summary: Indonesian guidelines on polycystic ovary syndrome management |
|
Mila Maidarti1,2,3, Achmad Kemal Harzif1,2,3, Amalia Shadrina2,3, Nafi'atul Ummah3, Wiryawan Permadi1,4, Polycystic Ovary Syndrome (PCOS) Guideline Collaboration Group5 |
1Indonesian Reproductive Endocrinology and Fertility Association, Indonesian Society of Obstetricians and Gynecologists Association, CITY, Indonesia
2Reproductive Immunoendocrinology Division, Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia
3Human Reproduction, Infertility, and Family Planning Cluster, Indonesia Reproductive Medicine Research and Training Center, Faculty of Medicine Universitas Indonesia
4Reproductive Fertility Endocrinology Division, Department of Obstetrics and Gynecology, Dr. Hasan Sadikin Hospital, Faculty of Medicine Universitas Padjajaran, Bandung, West Java, Indonesia
5Members of the Polycystic Ovary Syndrome (PCOS) Guideline Collaboration Group, CITY, COUNTRY |
Correspondence:
Achmad Kemal Harzif,
Email: kemal.achmad@gmail.com
|
|
Received: 10 September 2024 • Revised: 26 December 2024 • Accepted: 9 March 2025 |
| Abstract |
Objective
Polycystic ovary syndrome (PCOS) is a gynecological, endocrine condition characterized by ovulatory disorders, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. PCOS has significant metabolic and reproductive implications that affect the quality of life of women. This PCOS guideline summary is based on the Indonesian Reproductive Endocrinology and Fertility Association guidelines for PCOS. This guideline is expected to guide the diagnosis and long-term management of PCOS.
Methods
We searched scientific evidence on the Cochrane and PubMed databases using the keyword "polycystic ovary syndrome”. This evidence was reviewed by experts in the field of obstetrics and gynecology, and recommendations were made based on scientific evidence while considering patient values, costs, and resources.
Results
A total of 127 recommendations and practice points were made regarding the diagnosis and management of PCOS. The levels of available health services and management algorithms for PCOS in Indonesia are also included.
Conclusion
The first-line treatment for managing hyperandrogenism and menstrual disorders in patients with PCOS is combined oral contraceptives. The first-line treatment for ovulation induction is letrozole, while clomiphene citrate, metformin, gonadotropins, and ovarian surgery serve as the second-line treatment. The third-line treatments included in vitro fertilization, with or without in vitro maturation. |
| Key Words:
PCOS, Polycystic ovary syndrome, Guideline, Consensus, Indonesia |
|
PDF Links
Full text via DOI
Download Citation
